Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight ...

After years of weight loss drug shortages, the FDA is saying there’s now an adequate supply for most medications and they ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight ...

From STAT’s Elaine Chen: A federal judge this week ruled against a compounding trade group that wanted to continue making ...

Weight has always been an issue for me. But after two kids and the start of perimenopause, the weight just wasn't coming off ...

A code of secrecy surrounds the drug’s prevalence on campuses and in sororities.” ...

Consumers will have a bit longer to get compounded semaglutide, which is sold under the brands Wegovy for weight loss and Ozempic for diabetes. In December, the FDA declared Eli Lilly's ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

The FDA has declared that the shortage of popular weight-loss drugs, including Ozempic and Wegovy, is officially over.